AXL Y821F
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene AXL
Variant Y821F
Impact List missense
Protein Effect loss of function - predicted
Gene Variant Descriptions AXL Y821F lies within the protein kinase domain of the Axl protein (PMID: 31825826). Y821F demonstrates reduced binding to Abl2 in the presence of ligand in cell culture (PMID: 31825826), and therefore, is predicted to lead to a loss of Axl protein function.
Associated Drug Resistance
Category Variants Paths

AXL mutant AXL inact mut AXL Y821F

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_021913.5
gDNA chr19:g.41259681A>T
cDNA c.2462A>T
Protein p.Y821F
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001699.6 chr19:g.41259708A>T c.2462A>T p.Y821F RefSeq GRCh38/hg38
NM_021913.4 chr19:g.41259681A>T c.2462A>T p.Y821F RefSeq GRCh38/hg38
NM_021913.5 chr19:g.41259681A>T c.2462A>T p.Y821F RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL Y821F head and neck squamous cell carcinoma sensitive Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F in culture, and delayed tumor growth in a cell line xenograft model (PMID: 32439698). 32439698
AXL Y821F head and neck squamous cell carcinoma no benefit Bemcentinib + Cetuximab Preclinical - Cell culture Actionable In a preclinical study, combining Bemcentinib (BGB-324) with Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F, but did not enhance inhibition compared to cells treated with Erbitux (cetuximab) alone in culture (PMID: 32439698). 32439698